LOUIS GABOURY, M.D., Ph.D., F.R.C.P.(C)
- Principal Investigator, Histology and Molecular Pathology research unit, Institute for Research in Immunology and Cancer
- Associate Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal
- Head, Molecular Oncology and Pathology Laboratory, Hôtel-Dieu de Montréal
- Head, Molecular Pathology Research Laboratory,
Centre de recherche du Centre hospitalier de l’Université de Montréal
- President, Quebec Association of Pathologists
AWARDS & HONOURS
- Teaching Excellence Award, Université de Montréal, 1997
- Télésphore Parizeau Award, 1978
TRAINING
- Postdoctoral training with Paul Jolicoeur, Institut de recherches cliniques de Montréal, 1988-1991
- Postdoctoral training with Connie Eaves, Terry Fox Laboratory, BC Cancer Research Centre, 1984-1988
- Ph.D. in experimental pathology, University of British Columbia, 1988
- Post-graduate diploma in anatomic-pathology, Université de Montréal, 1983
- Doctor of Medicine, Université de Montréal, 1978
RESEARCH SUPPORT
Louis Gaboury received his doctoral degree in medicine from the Université de Montréal in 1978. After completing a multidisciplinary medical internship at Hôtel-Dieu de Montréal Hospital, he undertook graduate studies in anatomic-pathology. Once admitted as anatomical pathologist by the Collège des médecins du Québec, the Royal College of Physicians and Surgeons of Canada and the College of American Pathologists, he pursued further training in experimental pathology at the BC Cancer Centre in Vancouver. He then completed a second postdoctoral fellowship in Molecular Biology at the Institut de recherches cliniques de Montréal.
Dr. Gaboury started his academic career at the Université de Montréal as Assistant Professor in 1991. At the same time, he joined the department of pathology at Hôtel-Dieu de Montréal Hospital where he established a Molecular Diagnosis laboratory while continuing to practice medical and surgical pathology. His research at the time sought to analyse point mutations arising in hereditary cancers such as RET mutations in MEN-2 A & MEN-2B syndrome and BRCA-1 & BRCA-2 mutations in familial breast cancers. More recently, he set up the assays for molecular testing for colon cancer arising in the context of defects in Mismatch Repair Genes (MSH-2, MLH-1 and MSH-6).
Dr. Gaboury then became interested in developing molecular tools to assay the overexpression of the HER-2 oncogene. He was able to establish the FISH assay to determine the presence or absence of gene amplification in his laboratory. Because of his expertise, he was appointed member of the National Standards Committee that establishes Canadian guidelines for HER-2 immunhistochemistry assays.
His interest in breast pathology led him to study the human myoepithleial cell lineage during breast development and during breast cancer progression. His research in this area has led to the characterization of the human myoepithlial cell during breast development as well as in the normal and diseased breast tissues.
Since 2003, Dr. Gaboury has been collaborating with Thallion Pharmaceutical (formerly Caprion) in three major projects aimed at the proteomic characterization of three cancers, namely breast, lung, and prostate.
In 2006, Dr. Gaboury was recruited by IRIC to direct its histology core facility. In 2009, he was named Principal Investigator at IRIC where he continues to provide high quality histological services and consultation, and to develop new methods and tools, such as telepathology. Dr. Gaboury divides his time between research, teaching and his clinical work which focuses on medical and surgical pathology.
SELECTED PUBLICATIONS
Giroux M, Delisle JS, Gauthier SD, Heinonen KM, Hinsinger J, Houde B, Gaboury L, Brochu S, Wu J, Hébert MJ & Perreault C. (2011).
SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage.
Blood. 117:1734-1744.
Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O & Basik M. (2010).
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
Int J Cancer. Sep 9. [Epub ahead of print].
Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F & Sonenberg N. (2010).
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.
Proc Natl Acad Sci U S A. 107:14134-14139.
Sartelet H, Ohta S, Barrette S, Rougemont AL, Brevet M, Regairaz M, Harvey I, Bernard C, Fabre M, Gaboury L, Oligny LL, Bosq J, Valteau-Couanet D & Vassal G. (2010).
High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma.
Histopathology. 56:607-616.
Demers M, Rose AA, Grosset AA, Biron-Pain K, Gaboury L, Siegel PM
& St-Pierre Y. (2010).
Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells.
Am J Pathol. 176:3023-3031.
Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L & Siegel PM. (2010).
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Clin Cancer Res. 16:2147-2156.
Bilodeau M, MacRae T, Gaboury L, Laverdure JP, Hardy MP, Mayotte N, Paradis V, Harton S, Perreault C & Sauvageau G. (2009).
Analysis of blood stem cell activity and cystatin gene expression in a mouse model presenting a chromosomal deletion encompassing Csta and Stfa2l1 .
PLoS One. 4:e7500.
Terry J, Torlakovic EE, Garratt J, Miller D, Köbel M, Cooper J, Bahzad S, Pilavdzic D, O’malley F, O’brien AE, Sengupta S, Alport E, Têtu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM & Gilks CB. (2009).
Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/
Immunohistochemistry.
Appl Immunohistochem Mol Morphol. 17:375-382.
Hassan S, Ferrario C, Sargovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucco I, Phillips C & Basik M. (2009).
The influence of tumor-host interactions in the SDF-1/CXCR4 Ligand/Receptor Axis in Determining Metastatic Risk in Breast Cancer .
American Journal of Pathology. 175:66-73.
Voisin L, Julien C, Duhamel S, Gopalhai K, Claveau I, Saba-El-Leil MK, Rodrigue-Gervais IG, Gaboury L, Lamarre D, Basik M & Meloche S. (2008).
Activation of MEK1 or MEK2 isoform is sufficent to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
BMC Cancer. 8:337.
Deslisle JS, Gaboury L, Bélanger MP, Tassé E, Yagita H & Perrault C. (2008).
GVHD causes failure of donor hematopoiesis and lymphopoiesis in IFN-γ receptor-deficient hosts. Blood. 112:2111-2119.
Top
<< Back to Investigators List
